- Home
- AKBA vs HRTX Comparison
AKBA vs HRTX Comparison
Compare AKBA & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- HRTX
- Stock Information
- Founded
- AKBA 2007
- HRTX 1983
- Country
- AKBA United States
- HRTX United States
- Employees
- AKBA N/A
- HRTX N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- AKBA Health Care
- HRTX Health Care
- Exchange
- AKBA Nasdaq
- HRTX Nasdaq
- Market Cap
- AKBA 336.2M
- HRTX 270.7M
- IPO Year
- AKBA 2014
- HRTX 1987
- Fundamental
- Price
- AKBA $1.80
- HRTX $1.73
- Analyst Decision
- AKBA Strong Buy
- HRTX Strong Buy
- Analyst Count
- AKBA 1
- HRTX 3
- Target Price
- AKBA $7.50
- HRTX $5.67
- AVG Volume (30 Days)
- AKBA 1.8M
- HRTX 1.2M
- Earning Date
- AKBA 03-13-2025
- HRTX 02-27-2025
- Dividend Yield
- AKBA N/A
- HRTX N/A
- EPS Growth
- AKBA N/A
- HRTX N/A
- EPS
- AKBA N/A
- HRTX N/A
- Revenue
- AKBA $169,879,000.00
- HRTX $137,737,000.00
- Revenue This Year
- AKBA N/A
- HRTX $13.10
- Revenue Next Year
- AKBA $19.31
- HRTX $14.03
- P/E Ratio
- AKBA N/A
- HRTX N/A
- Revenue Growth
- AKBA N/A
- HRTX 12.13
- 52 Week Low
- AKBA $0.80
- HRTX $1.04
- 52 Week High
- AKBA $2.48
- HRTX $3.93
- Technical
- Relative Strength Index (RSI)
- AKBA 28.80
- HRTX 52.86
- Support Level
- AKBA $2.07
- HRTX $1.63
- Resistance Level
- AKBA $2.17
- HRTX $1.83
- Average True Range (ATR)
- AKBA 0.08
- HRTX 0.10
- MACD
- AKBA -0.05
- HRTX -0.01
- Stochastic Oscillator
- AKBA 4.60
- HRTX 41.94
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.